Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. - sprookjes - yvandenbroek - TriplyDB

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

http://www.wikidata.org/entity/Q34661815

about

The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics Resistant mechanisms to BRAF inhibitors in melanoma Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Melanoma: oncogenic drivers and the immune system New developments in the management of advanced melanoma - role of pembrolizumab The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients Adaptive Immune Resistance: How Cancer Protects from Immune Attack Immune Checkpoint Blockade in Cancer Therapy New immunotherapies targeting the PD-1 pathway PD-1 and its ligands are important immune checkpoints in cancer The role of immune checkpoint inhibition in the treatment of ovarian cancer From mice to humans: developments in cancer immunoediting miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma PD-1 blockade induces responses by inhibiting adaptive immune resistance Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.Classifying Cancers Based on T-cell Infiltration and PD-L1.Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment.Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma.Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.Advances in immunotherapy for melanoma management.Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.

P2860

Q26738677-A991E9E4-088D-4130-B5D1-91FECAB8966D Q26739717-85FD587C-FAC8-4A1C-A770-3894770C32E1 Q26769734-4AEBCC3A-A7C6-449A-AD95-F4A16B9B69CC Q26771192-CF119876-0A0D-4770-B5B3-71D9E81D03D8 Q26775598-73C29925-417A-4646-87F0-D66CF62E4851 Q26781931-580A51BC-573F-4129-82E0-0102F8E8AB89 Q26797478-5C19D4C2-3347-44B9-955F-D949F14FED0B Q26798448-E49B9C94-6BC3-43D9-8E71-AC46F1EB30F9 Q26830509-0FD9873C-3FB3-4A73-B3C4-834EBB6A6C60 Q27010018-44F643F9-4027-4AEA-BC62-DC15C678B793 Q28069485-DD9D69A1-A444-4393-AF48-95B6D3784466 Q28077924-00009508-320A-4D40-B84E-D102980EDD45 Q28088304-E77B3127-CF6C-4042-80D6-EDB647945100 Q28397829-78055915-53C4-4E5E-8869-CBC61B5F90EE Q29620856-7C8C2580-5E49-44ED-A55E-60999A89E5D6 Q30746265-2747903C-5818-4583-BD4A-CE56711A80CB Q33814322-D6A0754E-322B-47E3-A294-A45DBAEFE8FD Q34667977-BAFF844E-89A4-4C76-A3D4-5B322CC1CCCF Q34786402-071FA40D-0116-4997-BDA4-4D87F3D8A2A7 Q34809019-1B2B2059-BF16-43DC-9D35-0768997B6F42 Q35154039-8EFFA2B5-AE0D-476F-A63D-BB14FC8004FA Q35674821-49CE3303-E964-402C-83DE-D0ADD5BD388D Q35713265-44470628-36FD-44FC-8482-3E719493E9CE Q35815273-B63A6A01-8DCE-41E7-AEBD-5CC2A98AC9FF Q36193035-D5B64142-F4E9-4680-B143-EC761242EBA6 Q36269232-DCD1FA79-D6AD-48ED-A910-2E343B8E0F41 Q36553576-EC144BE4-A117-447A-8CAC-5C4E9A9D82F7 Q36622089-55173A5C-B473-4884-8755-CEB2223EF3EA Q36954166-87324783-9144-46D9-9CF1-C88B5310AC2B Q37086237-BC399323-8EB5-483A-A287-2CE9072DCC6B Q37114367-1C8BC815-94AF-4848-BEEB-D3D535B9CC18 Q37222152-8EB6D1C7-2197-4C31-AEA3-2184BA5743F3 Q37222679-905EEC64-C04E-44C6-8D6A-A924C06997F1 Q37281262-222D9B06-40C9-477E-9702-FF80B56D4410 Q37375978-EBE07E66-E65A-4A35-B12E-DB88E38086AE Q37593573-A5655362-E690-4501-9F81-B2A9517B0BC0 Q37677845-D57F6D1C-7C28-449B-8C54-8C2AF89BEAA2 Q37716640-7B25EF22-E76D-44AE-85D0-71C3ADB33CC6 Q37718304-50B978E4-0525-4531-98C3-C804B815E8E5 Q38284898-02D2F186-3A34-4217-BEED-639707235C73

P2860

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

http://www.wikidata.org/entity/Q34661815

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@ast

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@en

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@nl

type

label

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@ast

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@en

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@nl

prefLabel

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@ast

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@en

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@nl

P1433

Q34661815-BDBB20AB-1E17-49E4-909F-D723C8C510EA

P1476

Q34661815-36DFCCDE-ED5F-438C-A7FF-EB8C3AA05362

P2093

Q34661815-09F4548F-3DFD-435A-A02C-7A26EF8F9491

Q34661815-1454E2C6-264B-405D-9C64-FEDE71AEC4CD

Q34661815-623C83D7-426D-4A23-BED7-55E863DA4E22

Q34661815-67A58043-B837-4EB1-9721-ECA378390048

Q34661815-73B4CFF3-CEE8-4EC1-9ED9-F1A62C408C5B

Q34661815-7B473FB7-3B27-412F-8626-9F27785754BC

Q34661815-A917B789-7555-4FC7-BEB4-F2E6B1E1817C

Q34661815-BFC62725-3EA7-4C8D-815A-D58AEA4B13DF

Q34661815-E7E2B72B-B954-413B-8514-F868E8663F89

Q34661815-ED5F23AD-2957-4846-B10E-DB085F76CF5B

P2860

Q34661815-019EEC7C-3DA1-4551-8358-C50C34E7332E

Q34661815-0526F32C-1BED-42AA-9EC6-684B02484E00

Q34661815-063C3E00-8E2A-4FA9-BEFB-0DACDF7A490A

Q34661815-08334D11-4A34-400A-B993-ADBD62835F68

Q34661815-10E70364-520D-4AA0-AAA7-8705C5F40C18

Q34661815-1A16DC94-F572-4CB2-9F88-A7E426DDF340

Q34661815-1DFC21B3-CCDF-4BEF-AE29-B9CE965678BC

Q34661815-241F962B-1E49-4598-BD65-6EE69EC3ABA4

Q34661815-36769A4F-4514-41B8-887C-D07C8439C9A6

Q34661815-3FFED5A0-3ED6-406E-91C1-18E819644772

P304

Q34661815-BA76FD2D-469A-46F4-9F58-D6DA86B9C26A

P31

Q34661815-4E4B469B-5FF6-401A-8980-94878A9BC89F

P356

Q34661815-1201B25B-8E0B-41F5-9660-B7B476FE3043

P407

Q34661815-48971899-D411-4240-AB9C-5A0C045B11A1

P433

Q34661815-5EAE2CC8-1013-471D-BFC8-BD99B2A6B6FA

P478

Q34661815-1103142C-644D-421D-A091-9CACBF4471FB

P50

Q34661815-8540C66E-68BD-44CA-9087-00CDC4685C59

Q34661815-F9241F9E-492F-4921-8D10-5AE100371531

P577

Q34661815-C890F8D2-F95B-4CA2-A776-7240D560531C

P698

Q34661815-0FCFE3FF-094F-436C-B78A-BC76560BC60F

P932

Q34661815-18BC74DE-C188-4A9D-B24E-95BAF0E05D40

P356

1078-0432.CCR-13-2797

P1433

Clinical Cancer Research

P1476

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

@en

P2093

Amanda Lassen

http://www.w3.org/2001/XMLSchema#string

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Begonya Comin-Anduix

http://www.w3.org/2001/XMLSchema#string

David Foulad

http://www.w3.org/2001/XMLSchema#string

Deborah J L Wong

http://www.w3.org/2001/XMLSchema#string

Earl Avramis

http://www.w3.org/2001/XMLSchema#string

Lidia Robert

http://www.w3.org/2001/XMLSchema#string

Michael Cerniglia

http://www.w3.org/2001/XMLSchema#string

Mohammad Atefi

http://www.w3.org/2001/XMLSchema#string

Thinle Chodon

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

Nivolumab plus ipilimumab in advanced melanoma.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

P304

3446-3457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-2797

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24812408

http://www.w3.org/2001/XMLSchema#string

P932

4079734

http://www.w3.org/2001/XMLSchema#string